New approaches in the therapy of the peripheral vascular ulcer.
It can readily be seen that Debrisan represents a more effective mode of therapy for several groups of patients which tend to have chronic disabling ulcers of limbs of various etiologies, including venous stasis ulcers, chronic sickle-cell ulcers, decubiti, etc. The more effective treatment of this patient populations, which is provided by Debrisan, would provide a very significant decrease in the total cost of health care in the United States, approximating half a billion dollars per year.
D000293:Adolescent; D003911:Dextrans / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007871:Leg Ulcer / Q000188:drug therapy* / Q000628:therapy; D008134:Long-Term Care; D008875:Middle Aged; D012959:Socioeconomic Factors; D013997:Time Factors; D014680:Veins
D003911:Dextrans